Sandoz To Seek Omnitrope Therapeutic Equivalence With Genotropin
Executive Summary
Sandoz plans to submit additional data to FDA to establish therapeutic substitutability for its follow-on human growth hormone product Omnitrope
You may also be interested in...
AB Or Not AB? Barr & Sandoz Ponder The Biogeneric Substitution Question
Generic manufacturers may not want substitutability for follow-on biologics, Barr CEO Bruce Downey said Sept. 19 at the Generic Pharmaceutical Association Annual Policy Conference in Washington, D.C
AB Or Not AB? Barr & Sandoz Ponder The Biogeneric Substitution Question
Generic manufacturers may not want substitutability for follow-on biologics, Barr CEO Bruce Downey said Sept. 19 at the Generic Pharmaceutical Association Annual Policy Conference in Washington, D.C
Pfizer’s Omnitrope Options Include Approval Challenge, Substitutability Fight
Pfizer's response to the approval of Sandoz' Omnitrope could signal the extent to which industry gauges the legality of approving follow-on biologics under the 505(b)(2) pathway